Patent 12018089 was granted and assigned to Incyte on June, 2024 by the United States Patent and Trademark Office.
Anti-CD73 antibodies are disclosed. Also disclosed are related nucleic acids, vectors, cells, and pharmaceutical compositions. Methods of treating cancer with the anti-CD73 antibodies are also disclosed.